Business Context and Reporting Period
This Form 8-K Current Report, dated June 9, 2023, pertains to Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company. The filing reports significant changes in executive leadership, specifically the resignation of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Resignation of CFO: David A. Spellman resigned as Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer, and principal accounting officer, effective June 23, 2023.
- Interim Leadership: John P. Butler, President and CEO, will serve as interim principal financial officer and principal accounting officer from June 23, 2023, until July 17, 2023.
- Appointment of New CFO: Ellen Snow was appointed to succeed Mr. Spellman, effective July 17, 2023.
Compensation, Outlook, and Risks
Separation Arrangements (David A. Spellman)
Mr. Spellman is eligible for a separation agreement including:
- 12 months of base salary continuation.
- Up to 12 months of COBRA premium reimbursement for health and dental coverage.
- Continued vesting of unvested equity and equity-based awards during the severance period.
- Conditions include execution of a general release of claims and compliance with restrictive covenants.
Compensation Package (Ellen Snow)
Ms. Snow's offer letter includes:
- Base Salary: $450,000 annually.
- Bonus Target: 45% of base salary.
- Equity Grants (Effective July 31, 2023):
- 560,000 stock options (vesting over 4 years: 25% at first anniversary, remainder quarterly).
- 370,000 restricted stock units (vesting over 3 years: one-third annually).
- Execution of standard Indemnification and Executive Severance Agreements.
Risks and Contingencies
The filing notes that severance payments to Mr. Spellman are contingent upon his timely execution of a general release and compliance with non-competition and non-disparagement covenants.
Investor Verification Checklist
- Verify the exact vesting schedules and exercise prices for the 560,000 options and 370,000 RSUs granted to Ms. Snow.
- Confirm the total cash cost of Mr. Spellman's 12-month salary continuation and COBRA reimbursement.
- Review the specific terms of the Executive Severance Agreement referenced in the 2023 Proxy Statement to understand potential future liabilities.
- Monitor the transition period between June 23 and July 17, 2023, for any operational disruptions in financial reporting.